Tuesday, 24 May 2005 - 2:10 PM

This presentation is part of: Molecular Modeling throughout the Drug Discovery Process II

Design of New AIDS Drugs: A Multi-disciplinary Attack on the Problem of Drug Resistance

Kalyan Das1, Arthur D. Clark1, Yulia Volovik Frenkel1, Paul J. Lewi2, Jan Heeres2, Marc R. de Jonge2, Lucien M. H. Koymans2, Paul A.J. Janssen2, Donald W. Ludovici3, Bart De Corte3, Robert W. Kavash3, Chih Y. Ho3, Hong Ye3, Mark. A. Lichtenstein3, Michael J. Kukla3, Rudi Pauwels4, Koen Andries4, Marie-Pierre de Béthune4, Stephen H. Hughes5, and Eddy Arnold6. (1) Center for Advanced Biotechnology and Medicine, and Rutgers University, Piscataway, NJ, (2) Center for Molecular Design, Belgium, (3) Janssen Research Foundation, Spring House, PA, (4) Tibotec, Mechelen, Belgium, (5) HIV Drug Resistance Program, Frederick, (6) Rutgers University, Piscataway, NJ

Drug resistance is a primary cause of AIDS treatment failure. A multidisciplinary effort [1] led to the discovery of the potent diaryl-pyrimidine (DAPY) nonnucleoside inhibitors (NNRTIs) dapivirine, etravirine, and rilpivirine that are under clinical evaluation. Synthesis of a large number of compounds, determination of efficacy of the compounds against multiple HIV-1 strains, and systematic structural and molecular modeling studies of HIV-1 reverse transcriptase (RT) in complexes with NNRTIs were the key components of the drug design effort. The structural and modeling studies revealed different modes of binding for the DAPY inhibitors [2]. The torsional flexibility ("wiggling") of the inhibitors can generate numerous conformational variants and the compactness of the inhibitors permits repositioning and reorientation (translation and rotation) within the pocket ("jiggling"). Such adaptations appear to be critical for the ability of the NNRTIs to retain their potency against a wide range of drug-resistant HIV-1 RTs. Exploitation of inhibitor conformational flexibility can be a powerful element of drug design, especially for the design of drugs that will be effective against rapidly mutating targets. [1] Janssen P.A.J. et al. J. Med. Chem. 2005, 48: 1901. [2] Das et al. J. Med. Chem. 2004, 47, 2550.

Back to Molecular Modeling throughout the Drug Discovery Process II
Back to The 37th Middle Atlantic Regional Meeting (May 22-25, 2005)